Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults and Elderly

Inclusion Criteria: * Healthy volunteer ≥ 2 years old; * Proven legal identity; * Written consent of the guardian of participants \< 18 years old, and written consent of the participant ≥ 12 years old; * Complying with the requirement of the study protocol; Exclusion Criteria: * Prior vaccination with pneumococcal vaccine; * History of bacterial pneumonia within 3 years prior to this study; * Pregnant, breast feeding, or women expected to conceive within 60 days after vaccination; * History of allergy to any vaccine or vaccine ingredient; * Receipt of any of the following products: 1. Blood product within 3 months prior to study entry; 2. Any live attenuated vaccine within 28 days prior to study entry; 3. Any subunit vaccine or inactivated vaccine within 14 days prior to study entry; 4. Any immunosuppressant within 6 month prior to study entry; * Congenital malformation, developmental disorders, serious chronic diseases, autoimmune disease, immunodeficiency, serious cardiovascular disease, diabetes, hypertension that cannot be stabilized by medication, liver or kidney disease, or malignant tumor; * History of asthma, thyroidectomy, angioneurotic edema, severe nervous system disease or mental illness; without spleen or splenectomy; diagnosed coagulation function abnormal (e.g., coagulation factor deficiency, coagulation disorder, or platelet abnormalities), or obvious bruising or coagulation disorders; * Acute disease or acute stage of chronic disease within 7 days prior to study entry; * Axillaty temperature \> 37.0 °C; * Any other factor that in the opinion of the investigator suggesting the volunteer is unsuitable for this study; * Participants with the following conditions from day 0 - 28 would be included in the full analysis set (FAS), but would be excluded from the per protocol set (PPS): 1. Receipt of any other investigational or unregistered product (drug or vaccine); 2. Receipt of immunosuppressant (corticosteroid dosage that equivalent to or above 0.5 mg prednisone/kg weight/day) for \> 14 days, except for inhalant or locally administrated corticosteroid; 3. Receipt of immunoglobulin and/or blood product; 4. Newly diagnosed autoimmune disease or immunodeficiency (e.g., HIV infection);